English

Modus Therapeutics publishes interim report for the third quarter 2021

Report this content

STOCKHOLM, SWEDEN - 18 November 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the third quarter 2021. The interim report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.

The third quarter in figures

  • The loss after tax amounted to TSEK 4 441 (697).
  • The loss per share amounted to SEK 0,30 (0,12)
  • The cash flow from current operations was negative in the amount of TSEK 4 226 (942)

The first nine-months in figures

  • The loss after tax amounted to TSEK 8 402 (5 000).
  • The loss per share amounted to SEK 0,76 (1,00).
  • The cash flow from current operations was negative in the amount of TSEK 7 691 (6 124)
  • Cash and cash equivalents amounted to TSEK 29 035 (3 452)

Important events during the third quarter

  • Modus Therapeutics is listed on Nasdaq First North Growth Market.
  • Modus Therapeutics appoints Key Scientific Advisors.

Important events after the end of the third quarter

  • Symbiosis Pharmaceutical Services starts producing sevuparin for Modus’ future clinical development in sepsis/septic shock.
  • Modus Therapeutics engages Lago Kapital as a liquidity guarantor.
  • Modus Therapeutics Receives Regulatory Approval to Start Phase 1b Clinical LPS Challenge Study with Sevuparin in the Netherlands.

The Q3 2021 results will also be presented at an investor webcast today November 18th at 11:00 CET. The webcast can be accessed via the following link  https://youtu.be/l3uPswQwUic or via the Modus website.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Documents & Links